



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Flannery et al.

Serial No: 09/463,844

Attorney Docket No. ASZD-P01-251

Filed: February 1, 2000

Art Unit: 1646

For: ZGGBP1, Novel Peptides Related to
Bipolar Affective Disorders Type 1,
Sequences and Uses Thereof.

Examiner: Olga N. Chernyshev

RECEIVED
FEB 06 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

January 28, 2003

Date of Signature
and of Mail Deposit

Mary Jane DiPalma

Commissioner for Patents
Washington, D.C. 20231

REPLY UNDER 37 CFR 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed August 8, 2002, in connection with the above application. A Notice of Appeal and Petition for a three-month extension of time and appropriate fees are filed concurrently herewith.

REMARKS

Claims 10-12 and 17 have been rejected under 35 U.S.C. § 101 because "the claimed invention is drawn to an invention with no apparent or disclosed specific and substantial credible utility." Specifically, the Examiner asserts that "the instant application does not disclose the biological role of this protein or its significance." The Examiner further objects to the specification under 35 U.S.C. § 112, first paragraph, for the same reasons. Applicants respectfully traverse these rejections for the reasons that follow.